CatalystMarker
← board

HCM

Shanghai Hutchison Pharmaceuticals Limiteddistress 1/10 · well-funded / low risk
$11.12-1%today-42% from 52w high
hutch-med.com1,796 employeesFounded 2000Hong Kong, Hong KongDrug Manufacturers - Specialty & Generic
Lead: Adult
Revenue
$549M
Liquidity
$1367M
Runway
21.1 yrs
Shares 1y
0%

Price & events

-28.0% over 6M
$9.99$12.86$15.74Jan 26Apr 26Jul 26177krating: B of A Securities: Buy (2026-07-07)rating: B of A Securities: Buy (2026-03-10)
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-4.1%
1W
+11.3%
1M
-23.6%
3M
-28.0%
6M
-37.1%
1Y
-45.0%
2Y
-73.5%
5Y
-67.3%
All

Overview

Market Cap
$9.70B
Enterprise Value
$9.70B
Volume
75.10K
52 Week Range
$9.99 – $19.21
Total Shares
872.33M
Float Shares
102.72M
Short %
0.19%
% Held by Insiders
0.01%
% Held by Institutions
2.57%
RVOL
1.49x
Beta
0.43

Pipeline stages · 5 programs

HMPL-A580
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12
SHPL-49 Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-30
Savolitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-05-30
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-05-31
fruquintinib, sintilimab, paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01-08

Pipeline · 11 trials · 11 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-12
Estimated 50%
readout ~2026-12-31
Phase 1HMPL-306Gliomas Harboring IDH1 and/or IDH2 Mutations—recruiting
2027-06-30
Estimated 50%
readout ~2027-09-13
Phase 3SHPL-49 InjectionAcute Ischemic Stroke—recruiting
2027-10-08
Estimated 50%
readout ~2027-11-07
Phase 1HMPL-506Hematological Malignancies—recruiting
2028-04-30
Estimated 50%
readout ~2028-07-14
Phase 3HMPL-760, R-GemOxRelapsed/Refractory Diffuse Large B-Cell Lymphoma—recruiting
2028-05-30
Estimated 50%
readout ~2028-08-13
Phase 3SavolitinibNon-small Cell Lung Cancer—active not recruiting
Show all 11 trials · 6 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2028-05-31
Estimated 50%
readout ~2028-08-14
Phase 2/3Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and GemcitabineMetastatic Pancreatic Cancer—recruiting
2028-06-30
Estimated 50%
readout ~2028-09-13
Phase 2/3HMPL-453Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult—recruiting
2028-11-30
Estimated 50%
readout ~2029-01-14
Phase 1/2HMPL-A251Solid Tumors, Adult—recruiting
2028-12-31
Estimated 50%
readout ~2029-02-14
Phase 1/2HMPL-A580Solid Tumors, Adult—recruiting
2028-12-31
Estimated 50%
readout ~2029-03-16
Phase 3HMPL-306 Regimen, Salvage Chemotherapy RegimenAcute Myeloid Leukemia—recruiting
2029-01-08
Estimated 50%
readout ~2029-03-24
Phase 3fruquintinib, sintilimab, paclitaxelAdvanced Endometrial Cancer—recruiting

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 872,327,620 · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $23 (+103% upside) · 14 analysts
  • 2026-07-07B of A SecuritiesBuy
  • 2026-03-10B of A SecuritiesBuy
  • 2025-09-22Morgan StanleyEqual-Weight → Underweight
  • 2025-07-22B of A SecuritiesBuy
  • 2024-08-01Goldman SachsNeutral

Competitors — Adult

  • PFEPFIZER INC$142.2B · D3
  • BEIGFBeOne Medicines Ltd.$31.7B · D1
  • PCVXVaxcyte, Inc.$8.0B · D2
  • COGTCogent Biosciences, Inc.$6.7B · D6
  • EWTXEdgewise Therapeutics, Inc.$4.1B · D4
  • RLAYRelay Therapeutics, Inc.$3.6B · D6
  • TYRATyra Biosciences, Inc.$1.8B · D3
  • MNPRMonopar Therapeutics$687M · D1
  • AUTLAutolus Therapeutics plc$378M · D8
  • ENTAENANTA PHARMACEUTICALS INC$373M · D5

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.